Se si usano dosi appropriate (4g) di omega3 e non basse (1g) come negli ultimi studi presentati si ottiene una riduzione della mortalità cardiovascolare del 25%.
https://www.medscape.com/viewarticle/902478#vp_1
REDUCE-IT: 25% Reduction in MACE With High-Dose EPA
Sue Hughes
September 25, 2018
High doses (4-g daily) of the omega-3 oil eicosapentaenoic acid (EPA) have shown a large benefit on cardiovascular events in the randomized, double-blind REDUCE-IT trial.
Top-line results of the trial were announced yesterday in a press release by the sponsor, Amarin, which manufactures the high-dose EPA product under the brand name Vascepa.
https://investor.amarincorp.com/news-releases/news-release-details/reduce-ittm-cardiovascular-outcomes-study-vascepar-icosapent
Inviato dal mio iPhone utilizzando Tapatalk